Details of the Drug

General Information of Drug (ID: DMPW5UF)

Drug Name
Avalglucosidase alfa
Indication
Disease Entry ICD 11 Status REF
Pompe disease 5C51.3 Approved [1]
Affected Organisms
Humans and other mammals
ATC Code
A16AB22: Avalglucosidase alfa
A16AB: Enzymes
A16A: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A: ALIMENTARY TRACT AND METABOLISM
Drug Type
Recombinant protein
Sequence
QQGASRPGPRDAQAHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQG
LQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETE
NRLHFTIKDPANRRYEVPLETPRVHSRAPSPLYSVEFSEEPFGVIVHRQLDGRVLLNTTV
APLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHP
FYLALEDGGSAHGVFLLNSNAMDVVLQPSPALSWRSTGGILDVYIFLGPEPKSVVQQYLD
VVGYPFMPPYWGLGFHLCRWGYSSTAITRQVVENMTRAHFPLDVQWNDLDYMDSRRDFTF
NKDGFRDFPAMVQELHQGGRRYMMIVDPAISSSGPAGSYRPYDEGLRRGVFITNETGQPL
IGKVWPGSTAFPDFTNPTALAWWEDMVAEFHDQVPFDGMWIDMNEPSNFIRGSEDGCPNN
ELENPPYVPGVVGGTLQAATICASSHQFLSTHYNLHNLYGLTEAIASHRALVKARGTRPF
VISRSTFAGHGRYAGHWTGDVWSSWEQLASSVPEILQFNLLGVPLVGADVCGFLGNTSEE
LCVRWTQLGAFYPFMRNHNSLLSLPQEPYSFSEPAQQAMRKALTLRYALLPHLYTLFHQA
HVAGETVARPLFLEFPKDSSTWTVDHQLLWGEALLITPVLQAGKAEVTGYFPLGTWYDLQ
TVPIEALGSLPPPPAAPREPAIHSEGQWVTLPAPLDTINVHLRAGYIIPLQGPGLTTTES
RQQPMALAVALTKGGEARGELFWDDGESLEVLERGAYTQVIFLARNNTIVNELVRVTSEG
AGLQLQKVTVLGVATAPQQVLSNGVPVSNFTYSPDTKVLDICVSLLMGEQFLVSWC
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 1,290 +/- 420 mgh/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 259 +/- 72 mg/L [2]
Clearance
The clearance of drug is 0.9 L/h [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.6 hours [2]
Metabolism
The drug is metabolized via the catabolic pathways [2]
Vd
The volume of distribution (Vd) of drug is 3.4 L [2]
Cross-matching ID
UNII
EO144CP0X9
DrugBank ID
DB16099
TTD ID
D34SXJ

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lysosomal alpha-glucosidase (GAA) TTLPC70 LYAG_HUMAN Replacement [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761194.
2 FDA Approved Drug Products: NEXVIAZYME (avalglucosidase alfa-ngpt) for injection, for intravenous use
3 ClinicalTrials.gov (NCT02782741) Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease (COMET). U.S. National Institutes of Health.